LeMaitre Vascular, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the three and nine months ended September 30, 2026.

Key Highlights

  • Quarterly net sales: $67,970,000 for the three months ended September 30, 2026, compared with $61,046,000 in the same period of 2025, according to the filing.
  • Quarterly net income: $15,024,000 for the three months ended September 30, 2026, versus $17,362,000 in the prior-year quarter, as reported.
  • Diluted earnings per share: $0.65 for the third quarter of 2026, compared with $0.75 in the third quarter of 2025.
  • Nine-month net sales: $204,903,000 for the nine months ended September 30, 2026, versus $185,149,000 in the same prior-year period.
  • Cash dividends declared per common share: $0.25 for the three months ended September 30, 2026, compared with $0.20 in the three months ended September 30, 2025.
  • Total stockholders' equity: $432,131,000 as of September 30, 2026, up from $393,516,000 at December 31, 2025.
  • Shares outstanding: 22,880,871 shares of common stock as of November 2, 2026, per the filing's cover page.

LeMaitre Vascular Third-Quarter 2026 Financial Results and Balance Sheet Position

LeMaitre Vascular, Inc. (NASDAQ:LMAT), a Delaware-incorporated medical device company headquartered in Burlington, Massachusetts, reported net sales of $67,970,000 for the three months ended September 30, 2026. Cost of sales for the same quarter totaled $19,265,000, producing gross profit of $48,705,000, according to the unaudited consolidated statements of operations included in the filing. Total operating expenses for the quarter were $31,010,000, and income from operations was $17,695,000.

For the nine months ended September 30, 2026, the company reported net sales of $204,903,000 and net income of $47,753,000, compared with net sales of $185,149,000 and net income of $42,152,000 for the nine months ended September 30, 2025. Investment income for the nine-month period was $10,075,000, and interest expense related to the company's convertible senior notes totaled $3,906,000, as disclosed in the filing. The provision for income taxes for the nine months ended September 30, 2026 was $13,782,000.

The consolidated balance sheet as of September 30, 2026 showed total assets of $656,032,000, including short-term marketable securities of $362,228,000 and goodwill of $65,945,000. Convertible senior notes, net, stood at $169,317,000. Total liabilities were $223,901,000, and retained earnings reached $215,324,000. The company had 1,629,267 shares held as treasury stock at a cost of $17,916,000 as of September 30, 2026, per the filing.

What Was Disclosed

LeMaitre Vascular's Form 10-Q for the quarter ended September 30, 2026 presented unaudited financial statements showing quarterly net sales of $67,970,000, net income of $15,024,000, diluted EPS of $0.65, and a cash dividend declared of $0.25 per common share for the three-month period.